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Abstract
Background: Pimecrolimus cream (Elidel®, SDZ ASM
981), a non-steroid inhibitor of inflammatory cytokines,
is effective in the treatment of atopic dermatitis (AD). We
assessed whether early treatment of AD signs/symp-
toms reduces the need for topical corticosteroids. Objec-
tive: To investigate the efficacy and safety of pimecroli-
mus cream 1% in the long-term management of adult
AD. Methods: 192 adults with moderate to severe AD
were randomised (1:1) for twice daily (b.i.d.) treatment of
early signs or symptoms of AD with either pimecrolimus
cream 1% or vehicle cream (control group) to prevent
progression to flares. Treatment was given as needed for
24 weeks. In the event of flares, a moderately potent cor-
ticosteroid (prednicarbate 0.25% cream) was permitted
as rescue medication in both groups. The percentage of
days on which a topical corticosteroid was used to treat
disease flares was the main outcome measure. Results:
Corticosteroid medication was used on 14.2% (95% con-
fidence interval, CI: 8.3–21.1) of the days of the 24-week
treatment period in the pimecrolimus group and on
37.2% (95% CI: 30.4–44.0) of the days in the control
group (p ! 0.001). In total, 44.8% (43/96) of patients in the
pimecrolimus group did not experience a flare compared
with 18.8% (18/96) of patients in the control group. The
median time to first flare was 144 days in the pimecroli-
mus group and 26 days in the control group (p ! 0.001).
Pimecrolimus treatment was also associated with im-
provement in signs and symptoms of AD, pruritus, pa-
tients’ self-assessment and quality of life. Conclusions:
Pimecrolimus cream 1% b.i.d. is an effective, well-toler-
ated, long-term treatment for AD in adults, substantially
reducing the number of flares compared to a convention-
al therapy and consequently reducing or eliminating the
need for corticosteroid treatment.
Copyright © 2002 S. Karger AG, Basel
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Introduction
Since the 1950s, treatment of atopic dermatitis (AD)
has combined the use of emollients for dry skin with reac-
tive use of topical corticosteroids for disease flares [1, 2].
Topical corticosteroids are effective in the treatment of
the acute signs and symptoms of AD, but many patients
and doctors are hesitant to use them in the long term [3,
4]. The primary concern with the long-term use of cortico-
steroids is the risk of local adverse effects with chronic
and inappropriate use, with skin atrophy as the foremost
concern [5, 6].
Pimecrolimus (Elidel®, SDZ ASM 981) offers a novel,
non-steroid approach to the future management of AD. It
is an anti-inflammatory macrolactam developed specifi-
cally for the treatment of inflammatory skin diseases [7].
Its mode of action is the selective inhibition of T-cell acti-
vation via the calcineurin pathway and inhibition of the
release of inflammatory cytokines from mast cells, there-
by preventing the cascade of immune and inflammatory
signals that drive the development of acute and chronic
AD [8, 9]. In contrast to corticosteroids, pimecrolimus
has no atrophogenic potential or other steroid-specific
side-effects [10].
This study investigated whether pimecrolimus cream
1%, when applied at the first signs or symptoms of AD
(e.g. mild erythema/pruritus), could prevent the disease
progressing to the point at which treatment with a moder-
ately potent topical corticosteroid would be required.
With this approach, topical corticosteroids could be re-
served for the treatment of acute severe disease, and the
corticosteroid side-effects associated with chronic treat-
ment could be avoided.
This was the first randomised, double-blind study
designed to assess the reduction in days on topical cortico-
steroids in AD as the primary outcome measure.
Participants
Study Design
This was a randomised, double-blind, parallel-group, multicentre
study in 12 dermatological university hospitals, 1 dermatological
clinic and 3 dermatology practices in Germany. Patients were
recruited from September 1999 to June 2000, and in total, 192 adult
patients, with a clinical diagnosis of AD according to the criteria of
Rajka [11], were randomised, 1:1, to receive treatment as needed
over 24 weeks with either pimecrolimus cream or a corresponding
vehicle cream, and emollients and reactive use of topical corticoste-
roids. Treatment was assigned by computer-generated randomisa-
tion lists. To maintain the study blind, a vehicle cream, of identical
appearance and odour to the pimecrolimus cream, was used in the
control group. The blinding was strictly maintained for all site moni-
toring and data management personnel at all times.
Inclusion Criteria
Patients were required to have AD affecting at least 5% of the
total body surface area and an Investigator’s Global Assessment
(IGA) score of 3 or 4. (For definition of IGA, see primary and second-
ary outcome measures.)
Exclusion Criteria
Therapies which led to exclusion were: PUVA, high-dose UVA
or systemic therapy with corticosteroids, immunosuppressants or
cytostatics (previous 3 months); topical therapies for AD (previous
2 weeks); systemic antibiotics (previous 2 weeks); systemic steroids
for indications other than AD (previous 1 month). Other exclusion
criteria comprised: pregnancy or lactation; women of child-bearing
age not using reliable contraception; need for treatment with potent
topical steroids for control of AD; severe concurrent allergic diseases;
diseases associated with immunosuppression or malignancy; pres-
ence of skin conditions that could affect the evaluation of study treat-
ment; active skin infections requiring treatment with a prohibited
medication, or active herpes simplex infections.
Planned Interventions
Patients applied the study medication (i.e. pimecrolimus cream
1% or corresponding vehicle) to the affected areas twice daily to treat
the first signs or symptoms of AD (e.g. pruritus, erythema) in order to
prevent progression to disease flare. A flare was defined as disease
status needing application of topical corticosteroid therapy for at
least 3 days. The study medication was applied twice daily to the
affected areas until complete clearance of signs and symptoms. Bland
emollients were applied to dry skin after application of the study
medication. A moderately potent topical corticosteroid, prednicar-
bate 0.25% cream (Dermatop®), was administered in both groups if
the patient experienced unacceptable itching and clinical signs (ooz-
ing/crusting or excessive scratch marks or severe erythema) despite
treatment with the study medication. Topical corticosteroid was to
be used for a maximum of 7 days b.i.d. followed by a further 7 days
o.d. or until marked reduction of the signs of AD was achieved. After
each course of corticosteroid there was a mandatory treatment for 7
days with the study drug (pimecrolimus cream or corresponding
vehicle) to treat residual disease and prevent rebound of the disease.
With the exception of cetirizine, no additional active treatment of
AD was allowed during the study. Patients were assessed at a screen-
ing visit (2 weeks to 2 days prior to randomisation), at baseline and at
weeks 1, 3, 6, 12 and 24. There was additional telephone contact
during weeks 9 and 18 and unscheduled visits in the event of flares.
Ethics
The study was performed according to Good Clinical Practice for
trials on medicinal products in the European Union and the Declara-
tion of Helsinki on medical research in humans. All patients gave
written informed consent, and the Institutional Review Board of the
principal investigator and the ethics committees of the individual
centres approved the study protocol.
Primary and Secondary Outcome Measures
The primary efficacy endpoint was the percentage of days on
which topical corticosteroid treatment was received. This endpoint
reflected the design of the study in which the principal aim was to
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assess the efficacy and safety of pimecrolimus in preventing exacer-
bation of the disease to the extent that treatment with corticosteroid
becomes necessary (i.e. a disease flare). Secondary outcome measures
included the number of disease flares, the time to first flare, IGA
scores, the Eczema Area and Severity Index (EASI) [12], a pruritus
severity assessment and patients’ self-assessment. Prior to the study,
all investigators were required to undergo training in IGA and EASI
assessments.
The IGA is a static (i.e. no reference to baseline state) 6-point
measure of disease severity, based on an overall assessment of skin
lesions: 0 (clear) = no inflammatory signs of AD; 1 (almost clear) =
just perceptible erythema and just perceptible papulation/infiltra-
tion; 2 (mild) = mild erythema and mild papulation and infiltration;
3 (moderate) = moderate erythema and moderate papulation/infil-
tration; 4 (severe) = severe disease with severe erythema and severe
papulation/infiltration; 5 (very severe) = severe erythema and severe
papulation/infiltration with oozing/crusting.
All patients with an IGA of ^2 were classified as treatment suc-
cess. The EASI is a composite, validated score objectively assessing
both the severity of the four key signs of AD (erythema, infiltration/
papulation, excoriations, lichenification) in the four body regions
(head/neck, trunk, upper and lower limbs) and the surface area
involvement. Combining the results from each region, age-adjusted
for the percentage of each body area involved, gives a total score in
the range of 0–72 [12].
In addition, the impact of treatment on patients’ quality of
life was assessed using two criteria, the Dermatology Life Quality
Index (DLQI) and the Quality of Life Index – Atopic Dermatitis
(QoLIAD). The DLQI comprises 10 questions regarding symptoms
and perception of disease, daily activities, work or school, personal
relationships, leisure and consequences of treatment. Each answer
was scored 0–3, giving a total index ranging from 0 (best) to 30
(worst) for quality of life. The DLQI is expressed as the percentage of
the maximum possible score of 30 [13]. The QoLIAD is a question-
naire with 25 items which could be answered with yes (score = 1) or
no (score = 0). The theoretical scale range is from 0 to 25. The
QoLIAD is expressed as the percentage of the maximum possible
score of 25. As with the DLQI, the higher the QoLIAD score, the
greater the impairment of quality of life [14].
All adverse events occurring during the study were recorded.
Physical examination and standard haematology, blood chemistry
and urinalysis tests were performed at regular scheduled visits
throughout the study. Patients also completed diaries on medication
use, changes in medical condition and pruritus (score of 0–4).
Statistical Analyses
The sample size was calculated as having to include at least 172
patients (86 in each group). This was based on the steroid consump-
tion (g/m2 body surface/week) seen in patients with AD, whereby the
consumption at the beginning of the reference study of 18 g/m2 is
compared to the consumption after 6 weeks of 6 g/m2. Statistical
analyses were performed on the intention-to-treat population defined
as all randomised patients to whom the study medication was dis-
pensed, with last observation carried forward employed to impute
missing data including endpoints. For the primary efficacy analysis,
the target parameter was the percentage of days on which topical cor-
ticosteroid medication was used, i.e. the number of days on topical
corticosteroid medication divided by the number of days from week
0 to week 24; patients discontinuing due to lack of efficacy or adverse
events were handled as if they had applied topical corticosteroids for
the rest of the study. The two treatment groups were compared using
the Wilcoxon rank sum test at the 5% significance level.
For secondary efficacy analysis, tests were used in an exploratory
manner. Treatment groups were compared using analysis of covar-
iance, Wilcoxon rank sum test, logistic regression or Fisher’s exact
test. Survival analytical methods (log-rank test) investigating the
time to first flare were also used. Cumulative survival curves investi-
gating the time to first flare were constructed by the Kaplan-Meier
method [15]. To investigate the effect of baseline variables with
respect to time to first flare, a Cox proportional hazards model was
fitted including the following factors: centre, baseline EASI score,
baseline IGA, age category and treatment group. The EASI was ana-
lysed using an analysis of covariance.
For quality of life assessments, summary statistics were calcu-
lated at each time point for each treatment group. The percentage
change from baseline was summarised in a similar manner.
Safety analysis was descriptive. Group comparisons for adverse
events were performed using Fisher’s exact test. For laboratory
parameters, differences between treatment groups were analysed by
the Wilcoxon rank sum test.
Results
Patients
Of the 192 patients from 16 centres who were random-
ised for treatment, 96 were randomised to the pimecroli-
mus-based treatment regimen and 96 to the control group.
A flow diagram of patient accounting and treatment out-
come is shown in figure 1. The demographic and clinical
characteristics of the patients are summarised in table 1.
There were no clinically or statistically significant demo-
graphic differences between the two groups at baseline.
The mean affected body surface area was 17.0% in the
pimecrolimus group and 16.9% in the control group. The
majority of patients in each group had moderate AD at
baeline (64.6 and 70.8% in the pimecrolimus and control
groups, respectively).
More patients in the control group than in the pime-
crolimus group discontinued prior to study completion
(37.5 vs. 22.9%, respectively). Discontinuation was due
mainly to an unsatisfactory therapeutic effect (27.1 vs.
15.6%, respectively). The time to discontinuation was sig-
nificantly longer in the pimecrolimus group (p ! 0.05).
Efficacy
Treatment with pimecrolimus cream 1% was associat-
ed with a significant reduction in the percentage of days
on which patients used corticosteroid medication (ta-
ble 2). In the pimecrolimus group, patients used cortico-
steroids on an average (mean) of 14.2% (95% confidence
interval, CI: 8.3–21.1) of 168 days (i.e. study duration)
compared with 37.2% (95% CI: 30.4–44.0) in the control
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Table 1. Baseline demographic and clinical characteristics of pa-
tients in the pimecrolimus and control treatment groups
Pimecrolimus 1%
(n = 96)
Control
(n = 96)
Age, years
Mean B SD 31.8B11.1 32.5B10.7
Median 28.5 29.5
Range 18U68 18U69
Sex
Male 36 (37.5) 41 (42.7)
Female 60 (62.5) 55 (57.3)
Total body surface area involved, %
Mean 17.0B7.6 16.9B10.7
Range 5.0U45.0 5.0U76.0
EASI
Mean 11.2B5.1 10.8B6.1
Range 2.0U26.6 2.8U35.3
IGA score
3 (moderate) 62 (64.6) 68 (70.8)
4 (severe) 33 (34.4) 28 (29.2)
5 (very severe) 1 (1.0) 0 (0.0)
Figures in parentheses indicate percentages.
Fig. 1. Flow of participants through the trial. ITT = Intention to
treat.
Table 2. Percentage of days of topical
corticosteroid treatment by baseline disease
severity
Treatment groups n Mean B SD Median Range p value1
All patients
Pimecrolimus 1% 96 14.2B24.2 2.1 0–97.0
!0.001Control 96 37.2B34.6 27.8 0–98.2
Moderate disease (IGA = 3)
Pimecrolimus 1% 62 9.5B19.8 0.0 0–97.0
!0.001Control 68 37.0B36.3 23.5 0–98.2
Severe disease (IGA = 4)
Pimecrolimus 1% 33 23.1B29.5 7.7 0–87.5 0.027Control 28 37.8B30.4 35.2 0–91.7
One patient with very severe disease (IGA = 5) is not shown in the table.
1 Wilcoxon rank sum test.
Pimecrolimus Cream in the Long-Term
Management of AD in Adults
Dermatology 2002;205:271–277 275
Fig. 2. Incidence of flares of AD in the pimecrolimus and control
treatment groups during the 6-month study.
Fig. 3. Kaplan-Meier estimate of time to first flare in the pimecroli-
mus and control treatment groups during the 6-month study.
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Fig. 4. Time course showing changes in pruritus scores during the
first week of treatment of AD with pimecrolimus cream 1% and a
corresponding vehicle cream. p ! 0.001 from day 3 onwards.
group (p ! 0.001). Forty-seven (49%) of the pimecroli-
mus-treated patients compared to 21/96 (21.9%) of those
in the control group did not use steroids at all.
The two treatment groups also showed significant dif-
ferences in the incidence of flares and the time to first
flare. In the pimecrolimus group, patients experienced a
mean of 1.1 (95% CI: 0.7–1.4) flares during the 24 weeks
of the study, compared to a mean of 2.4 (95% CI: 2.0–2.8)
flares in the control group (p ! 0.001). In total, 43/96
(44.8%) of patients in the pimecrolimus group had no
flares in the course of the study, compared with 18/96
(18.8%) in the control group. The incidence of flares is
summarised in figure 2. The estimated median time to
first flare was 144 days (95% CI: 105–1168) in the pime-
crolimus group and 26 days (95% CI: 21–47) in the con-
trol group (fig. 3).
Based on the IGA, 79/96 (82.3%) of patients in the
pimecrolimus group showed disease improvement from
baseline of at least 1 IGA score, and 66/96 (68.6%) were
classified as treatment success (IGA ^2). In contrast, an
improvement from baseline was recorded in 49/96
(51.0%) of the patients receiving a conventional therapy,
and the success rate was 36.5% (35/96). Similar results
were achieved according to the patients’ self-assessment
at week 24, with 62/96 (64.6%) of the patients in the
pimecrolimus group assessing their disease as completely
or well controlled compared with 34/96 (35.4%) of the
patients in the control group. Exploratory analysis of
treatment differences showed statistical significance for
both parameters (p ! 0.001).
Pruritus decreased within the first 2 days of treatment
with pimecrolimus but increased in the control group
(fig. 4). With the pimecrolimus-based treatment, the EASI
was reduced on average by 48.3%, from 11.2 to 5.7 (95%
CI: 4.1–6.9), whereas the decrease in the control group
was only 15.9%, from 10.8 to 8.8 (95% CI: 7.5–10.5; p !
0.001). Similar decreases were observed in the extent of
body surface area affected, namely a reduction of 48.4%
in the pimecrolimus group and 20.5% in the control group
(p ! 0.01).
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Quality of Life
Quality of life improved in both treatment groups dur-
ing the 6 months of the study, but the improvement was
significantly greater in the pimecrolimus group. The
mean decrease (i.e. improvement) in the QoLIAD score
was 25.6% in the pimecrolimus group, compared to 7.4%
in the control group (p = 0.002). Similarly, the mean
decrease (i.e. improvement) in the DLQI score in the
pimecrolimus group was 22.0%, compared to 6.7% in the
control group (p = 0.01).
Safety
Pimecrolimus was well tolerated, with a similar inci-
dence of drug-related adverse events in the pimecrolimus
(24.0%) and the control group (20.8%). Only 5 patients
discontinued due to adverse events. One patient in the
pimecrolimus group had an aneurysm, which was not sus-
pected of being related to the study medication. Four
patients in the control group discontinued due to adverse
events possibly related to the study medication. In 3
patients, contact dermatitis was suspected and 1 patient
had application site pain.
Local tolerability was good in both treatment groups.
The incidence of local adverse events was 39.6% (38/96) in
the pimecrolimus group and 36.5% (35/96) in the control
group. More patients in the pimecrolimus group than in the
control group experienced application site burning (10 vs. 3
patients, respectively), which resolved within 1–7 days.
In total, 18 (18.8%) of pimecrolimus-treated patients
and 9 (9.4%) of patients in the control group had at least 1
skin infection by month 6; this difference was not statisti-
cally significant (95% CI for the treatment difference:
–19.1 to 0.4). The imbalance was mainly due to a higher
number of herpes infections in the pimecrolimus group
(10 vs. 5) whereas the incidence rates of bacterial (4 vs. 3)
and fungal (2 vs. 1) infections were similar. Six of 10 cases
in the pimecrolimus group were herpes labialis (areas not
treated with the study medication) compared with 1 of 5
in the control group; there were 2 cases of eczema herpeti-
cum in the study, both in the control group.
No clinically relevant laboratory abnormalities were
observed during the study.
Discussion
The results of this 6-month study demonstrate for the
first time that pimecrolimus cream 1%, used at the first
signs or symptoms of AD, reduces or eliminates the need
for topical corticosteroids in adult patients.
Almost 50% of patients in the pimecrolimus cream 1%
group did not need any corticosteroid throughout the
study. When patients were stratified according to the
severity of disease at baseline, a marked reduction of days
requiring corticosteroid treatment was especially evident
in patients with moderate disease. The effect was much
more pronounced in patients with severe disease when the
median value rather than the mean value was considered,
since the latter is very susceptible to distortion by out-
liers.
The results of this study are consistent with the data of
two other trials [16, 17], which investigated the new pime-
crolimus-based treatment in children and infants. In both
those studies, the primary outcome measure was the
reduction in the incidence of flares, and the results were
similar to the present study. In those studies, the propor-
tion of patients experiencing no flares in 6 months in the
pimecrolimus group was 67.6% in infants (aged 3–23
months) and 61.0% in children (aged 2–17 years), com-
pared to 45% of the adult patients in the present study. In
the control groups, the respective flare-free incidences
were 30.4% for infants, 34.2% for children and 19% in the
present study. In all three studies the difference between
the pimecrolimus-based treatment and the conventional
therapy was statistically highly significant. The benefit of
treatment in adults was very similar to that in children in
spite of the higher incidence of flares in both groups in the
present study. Infants, 3–23 months of age, seem to derive
even more benefit than older children and adults from the
pimecrolimus-based treatment.
The time to first flare was more than 5 times longer in
the pimecrolimus group compared with the control group.
This illustrates the extent of the treatment effect and has
positive consequences for the patient’s well-being.
There were 10 cases of application site burning in the
pimecrolimus group compared with 3 in the control
group. However, the events were transient and did not
lead to discontinuation. Although there was no increase in
the incidence of bacterial or fungal infections, herpes sim-
plex infections were numerically more frequent in the
pimecrolimus group than in the control group. However,
this imbalance was not statistically significant and did not
take into account the longer average time spent in the
study by the patients in the pimecrolimus group. Further-
more, the imbalance was largely due to the higher number
of herpes labialis infections in the pimecrolimus group;
herpes labialis infections appear in areas not generally
affected by AD and hence were not treated with the study
medication (i.e. perioral).
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In conclusion, this study clearly demonstrated the ben-
efits of the new pimecrolimus-based treatment strategy in
adult AD. When used at the first signs or symptoms of
AD, pimecrolimus prevents the condition from progress-
ing to a flare and reduces or eliminates altogether the need
for topical corticosteroids. Reserving steroids for rescue
therapy will reduce the need for their long-term use and
minimise the risk of steroid-associated side-effects. In
addition to the steroid-sparing effect, pimecrolimus re-
duces the number of flares and improves overall disease
control of adult AD.
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